PPP2R2D, a regulatory subunit of protein phosphatase 2A, promotes gastric cancer growth and metastasis via mechanistic target of rapamycin activation

Yu,Shijun; Li,Li; Wu,Qiong; Dou,Ning; Li,Yandong; Gao,Yong

doi:10.3892/ijo.2018.4329

PPP2R2D, a regulatory subunit of protein phosphatase 2A, promotes gastric cancer growth and metastasis via mechanistic target of rapamycin activation

Authors:
- Shijun Yu
- Li Li
- Qiong Wu
- Ning Dou
- Yandong Li
- Yong Gao
View Affiliations

Affiliations: Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China
Published online on: March 20, 2018 https://doi.org/10.3892/ijo.2018.4329
Pages: 2011-2020

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein phosphatase 2A (PP2A) is an essential serine/threonine protein phosphatase that regulates the basic activities of eukaryotes by dephosphorylating its substrates. The function and substrate specificity of PP2A are generally determined by its regulatory subunits. In the present study, the clinical significance and roles of PPP2R2D, one of the regulatory subunits of PP2A, were demonstrated in gastric cancer (GC) carcinogenesis. Through a tissue microarray and quantitative polymerase chain reaction analysis, it was demonstrated that PPP2R2D was commonly upregulated in GC samples. This upregulation was positively correlated with the patients' tumor stage (P<0.01), T classification (P<0.01) and N classification (P=0.01). Furthermore, a high expression of PPP2R2D was closely associated with poor prognosis of patients. Knockdown of PPP2R2D significantly inhibited the proliferation and migration of GC cells in vitro, as well as the tumorigenicity and metastasis in vivo in an animal GC model. By contrast, overexpression of PPP2R2D promoted GC cell proliferation and migration in vitro. The analysis of underlying mechanisms indicated that PPP2R2D silencing decreased the phosphorylation level of mechanistic target of rapamycin (mTOR), thereby implicating that PPP2R2D is involved in the regulation of mTOR activity during tumorigenesis. Thus, the findings of the present study suggested that PPP2R2D may serve as a potential oncogene in GC and as a novel target for therapeutic strategies against this disease.

View Figures

View References

1	Hunter T: Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell. 80:225–236. 1995. View Article : Google Scholar
2	Janssens V and Goris J: Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 353:417–439. 2001. View Article : Google Scholar
3	Lechward K, Awotunde OS, Swiatek W and Muszyńska G: Protein phosphatase 2A: Variety of forms and diversity of functions. Acta Biochim Pol. 48:921–933. 2001.
4	Virshup DM: Protein phosphatase 2A: A panoply of enzymes. Curr Opin Cell Biol. 12:180–185. 2000. View Article : Google Scholar
5	Sontag E: Protein phosphatase 2A: The Trojan Horse of cellular signaling. Cell Signal. 13:7–16. 2001. View Article : Google Scholar
6	Seshacharyulu P, Pandey P, Datta K and Batra SK: Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 335:9–18. 2013. View Article : Google Scholar
7	Strack S, Chang D, Zaucha JA, Colbran RJ and Wadzinski BE: Cloning and characterization of B delta, a novel regulatory subunit of protein phosphatase 2A. FEBS Lett. 460:462–466. 1999. View Article : Google Scholar
8	Mayer RE, Hendrix P, Cron P, Matthies R, Stone SR, Goris J, Merlevede W, Hofsteenge J and Hemmings BA: Structure of the 55-kDa regulatory subunit of protein phosphatase 2A: Evidence for a neuronal-specific isoform. Biochemistry. 30:3589–3597. 1991. View Article : Google Scholar
9	Zolnierowicz S, Csortos C, Bondor J, Verin A, Mumby MC and DePaoli-Roach AA: Diversity in the regulatory B-subunits of protein phosphatase 2A: Identification of a novel isoform highly expressed in brain. Biochemistry. 33:11858–11867. 1994. View Article : Google Scholar
10	Janssens V, Goris J and Van Hoof C: PP2A: The expected tumor suppressor. Curr Opin Genet Dev. 15:34–41. 2005. View Article : Google Scholar
11	Li W, Xie L, Chen Z, Zhu Y, Sun Y, Miao Y, Xu Z and Han X: Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci. 101:1226–1233. 2010. View Article : Google Scholar
12	Schweyer S, Bachem A, Bremmer F, Steinfelder HJ, Soruri A, Wagner W, Pottek T, Thelen P, Hopker WW, Radzun HJ, et al: Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours. J Pathol. 213:72–81. 2007. View Article : Google Scholar
13	Duong FH, Dill MT, Matter MS, Makowska Z, Calabrese D, Dietsche T, Ketterer S, Terracciano L and Heim MH: Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53. Carcinogenesis. 35:114–122. 2014. View Article : Google Scholar
14	Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R and Zhuang Z: Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci USA. 106:11697–11702. 2009. View Article : Google Scholar
15	Boudreau RT, Conrad DM and Hoskin DW: Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T leukemia cells is negatively regulated by PP2A-associated p38 mitogen-activated protein kinase. Cell Signal. 19:139–151. 2007. View Article : Google Scholar
16	Zhuang Q, Zhou T, He C, Zhang S, Qiu Y, Luo B, Zhao R, Liu H, Lin Y and Lin Z: Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b. J Exp Clin Cancer Res. 35:672016. View Article : Google Scholar
17	Cunningham CE, Li S, Vizeacoumar FS, Bhanumathy KK, Lee JS, Parameswaran S, Furber L, Abuhussein O, Paul JM, McDonald M, et al: Therapeutic relevance of the protein phosphatase 2A in cancer. Oncotarget. 7:61544–61561. 2016. View Article : Google Scholar
18	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
19	Edge SB; American Joint Committee on Cancer: AJCC Cancer Staging Manual. Springer; New York: 2010
20	Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA, Reddel RR, et al: Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer. 127:1–8. 2010. View Article : Google Scholar
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
22	Rodgers JT, Vogel RO and Puigserver P: Clk2 and B56β mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt. Mol Cell. 41:471–479. 2011. View Article : Google Scholar
23	Zeng Q, Zhang H, Qin J, Xu Z, Gui L, Liu B, Liu C, Xu C, Liu W, Zhang S, et al: Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells. Cell Mol Life Sci. 72:4867–4884. 2015. View Article : Google Scholar
24	Sablina AA, Hector M, Colpaert N and Hahn WC: Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 70:10474–10484. 2010. View Article : Google Scholar
25	Kalev P, Simicek M, Vazquez I, Munck S, Chen L, Soin T, Danda N, Chen W and Sablina A: Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition. Cancer Res. 72:6414–6424. 2012. View Article : Google Scholar
26	Zhou P, Shaffer DR, Alvarez Arias DA, Nakazaki Y, Pos W, Torres AJ, Cremasco V, Dougan SK, Cowley GS, Elpek K, et al: In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 506:52–57. 2014. View Article : Google Scholar
27	Eichhorn PJ, Creyghton MP and Bernards R: Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta. 1795:1–15. 2009.
28	Letourneux C, Rocher G and Porteu F: B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J. 25:727–738. 2006. View Article : Google Scholar
29	Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY and Chiang CW: Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem. 283:1882–1892. 2008. View Article : Google Scholar
30	Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell. 124:471–484. 2006. View Article : Google Scholar
31	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar
32	Chen L, Xu B, Liu L, Liu C, Luo Y, Chen X, Barzegar M, Chung J and Huang S: Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Oncotarget. 6:7136–7150. 2015.
33	Bai H, Li H, Li W, Gui T, Yang J, Cao D and Shen K: The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget. 6:25520–25532. 2015. View Article : Google Scholar
34	Zhang Q and Claret FX: Phosphatases: The new brakes for cancer development? Enzyme Res. 2012:6596492012. View Article : Google Scholar